Phase I study of Vidaza [azacitidine] and Velcade (bortezomib) in acute myeloid leukaemia.

Trial Profile

Phase I study of Vidaza [azacitidine] and Velcade (bortezomib) in acute myeloid leukaemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Azacitidine (Primary) ; Bortezomib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 May 2008 Status changed from initiated to recruiting, reported by ClinicalTrials.gov.
    • 28 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top